US 12,410,410 B2
Ketoreductase polypeptides for the synthesis of chiral compounds
Oscar Alvizo, Fremont, CA (US); Nicholas J. Agard, San Francisco, CA (US); Xinkai Xie, Castro Valley, CA (US); David Entwistle, San Carlos, CA (US); and Birgit Kosjek, Westfield, NJ (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Dec. 16, 2021, as Appl. No. 17/553,455.
Application 16/874,574 is a division of application No. 15/543,535, granted, now 10,696,953, issued on Jun. 30, 2020, previously published as PCT/US2016/016692, filed on Feb. 5, 2016.
Application 17/553,455 is a continuation of application No. 16/874,574, filed on May 14, 2020, granted, now 11,236,308.
Claims priority of provisional application 62/114,380, filed on Feb. 10, 2015.
Prior Publication US 2022/0106575 A1, Apr. 7, 2022
Int. Cl. C12N 9/04 (2006.01); C12P 7/02 (2006.01); C12P 7/40 (2006.01); C12P 17/12 (2006.01); C12P 41/00 (2006.01)
CPC C12N 9/0006 (2013.01) [C12P 7/02 (2013.01); C12P 7/40 (2013.01); C12P 17/12 (2013.01); C12P 41/002 (2013.01); C12Y 101/01184 (2013.01)] 6 Claims
 
1. An engineered polypeptide comprising an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 240, wherein the residue corresponding to X150 is a tryptophan, the residue corresponding to X173 is a non-polar or aliphatic residue, the residue corresponding to X211 is an aromatic, acidic, or polar residue, and wherein the residue corresponding to X249 is glycine and wherein said polypeptide has ketoreductase activity with at least 2-fold greater selectivity to the chiral compound 2a relative to chiral compound 2c as compared to SEQ ID NO:2.